KKR raises $6.5 billion for asset-backed financing
Asset-backed financing refers to loans backed by assets such as mortgages or royalties that have predictable cash flows. Such loans do not rely solely on a borrower's creditworthiness.
KKR said it had hauled in $5.6 billion for a fund, named KKR Asset-Based Finance Partners II, and about $1 billion from separate accounts focused on the same type of investments.
These funds give borrowers access to loans they might not get from banks, as traditional lenders have been pulling back from riskier loans due to strict regulations. The funds also offer firms such as KKR exposure to investments with consistent returns.
"The $6 trillion ABF market, expected to top $9 trillion by 2029, remains undercapitalized despite its rapid growth," KKR's Global Head of Private Credit, Daniel Pietrzak, said.
The latest fund attracted commitments from a wide base of investors, including pensions, sovereign wealth funds, insurers, asset managers and family offices, the company said.
KKR launched its ABF in 2016. It manages more than $74 billion in ABF assets under management.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Connecticut Sun will reportedly be sold for $325M and could relocate to Boston by 2027
The Connecticut Sun could be on the move by 2027 after a group led by Celtics minority owner Steve Pagliuca reportedly reached a deal to purchase the WNBA franchise for $325 million, according to the Boston Globe. [Join or create a Yahoo Fantasy Football league for the 2025 NFL season] The $325 million would be the highest price ever paid for a professional women's team. The deal, which will require approval from the WNBA's Board of Governors, would see Pagliuca spend $100 million for a new practice facility in Boston and for the Sun to move from Uncasville, Connecticut. This story will be updated.
Yahoo
4 minutes ago
- Yahoo
VeriSign (VRSN) Announced Increased Earnings
In July 2025, VeriSign expanded its buyback authorization and announced increased earnings, alongside a declared cash dividend. Despite these positive developments, the company's share price declined by 5.90% over the past month. This decline coincided with a broader market downturn, driven by global tariff uncertainties and disappointing job data. While VeriSign's solid financial results might have typically buoyed investor confidence, the market context placed downward pressure on its stock. The company's follow-on equity offering also added complexity to its share dynamics over this period, contributing to a challenging market performance. Every company has risks, and we've spotted 3 warning signs for VeriSign (of which 1 shouldn't be ignored!) you should know about. Rare earth metals are the new gold rush. Find out which 25 stocks are leading the charge. VeriSign's recent expansion of its buyback authorization and earnings increase, juxtaposed with a share price decline of 5.90% during July, showcases the complexity of market dynamics. This decline coincided with external market pressures like global tariff uncertainties and disappointing job data. Despite these pressures, VeriSign's solid financial results and strategic initiatives may support long-term growth. Notably, in the last year, VeriSign's total return, including dividends, was 41.76%, highlighting its strong performance over a broader timeline despite recent challenges. Comparatively, over the past year, VeriSign outperformed the US market, which returned 16.8%, and also exceeded the US IT industry with its 24.5% return. The company's ongoing initiatives, such as improving domain registration trends and marketing strategies, could positively impact revenue growth, while the introduction of dividends reflects financial stability that could enhance earnings forecasts. VeriSign's current share price of US$265.37 is below the analyst consensus price target of US$309.0, indicating a 16.44% discount, which resonates with the potential for value growth should the company's revenue and earnings forecasts materialize as expected. In light of our recent valuation report, it seems possible that VeriSign is trading beyond its estimated value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include VRSN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
4 minutes ago
- Yahoo
CRISPR Therapeutics (CRSP) Sees 47% Price Increase Over Last Quarter
CRISPR Therapeutics recently announced significant developments in its in vivo cardiovascular disease programs, notably CTX310 and CTX320, which may have contributed to the company's 47% share price increase over the last quarter. The company's inclusion in multiple indices further enhances its market presence, potentially impacting investor interest positively. Meanwhile, CRISPR reported a net loss in its Q1 earnings, although revenue increased year-over-year. Despite a volatile market backdrop, characterized by declining major indices due to weak job reports and tariff concerns, CRISPR's advancements in therapeutic programs and strategic index additions contrasted against broader market movements. We've spotted 1 risk for CRISPR Therapeutics you should be aware of. Uncover the next big thing with financially sound penny stocks that balance risk and reward. Over the past year, CRISPR Therapeutics reported a total shareholder return of 9.74%. While the company's shares outperformed the US Biotechs industry, which returned a decline of 8.4% over the same period, it lagged behind the broader US Market's 17.7% return. The favorable performance relative to its industry can be linked to its strategic advancements in cardiovascular disease programs and inclusion in various Russell indices. The recent developments highlighted in the introduction, particularly the positive updates in CRISPR's cardiovascular programs and index additions, could potentially influence expectations around future revenue and earnings. Analysts forecast strong revenue growth of 57.3% annually, despite the company's forecast to remain unprofitable over the next three years. Meanwhile, with the current share price at $56.09, the market seems to discount the consensus analyst price target of $80.91, reflecting a substantial perceived upside potential in the stock. This price movement suggests that investors might see potential growth opportunities, even as the company navigates its profitability challenges. The valuation report we've compiled suggests that CRISPR Therapeutics' current price could be quite moderate. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
